Intellia Therapeutics (NTLA) Income from Continuing Operations (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Income from Continuing Operations of 192166000.0 for Q1 2026, up 24.62% year-over-year from 154200361.59 in Q1 2025, and down 108.23% quarter-over-quarter from 92284000.0 in Q4 2025.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Income from Continuing Operations for 12 consecutive years, with 192166000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 24.62% year-over-year to 192166000.0; the TTM figure through Mar 2026 stood at 625095000.0 (up 6.34% YoY), while the FY2025 annual figure was 1326436000.0, down 4.47% from the prior year.
- Income from Continuing Operations eased to 192166000.0 in Q1 2026 per NTLA's latest filing, from 92284000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 92284000.0 in Q4 2025 and bottomed at 559526000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 201350647.06 across 5 years, with a median of 163355000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 80.49% — and 2025, when it tumbled 97.63%.
- Intellia Therapeutics' Income from Continuing Operations stood at 559526000.0 in 2022, then surged by 70.8% to 163355000.0 in 2023, then grew by 22.77% to 126166000.0 in 2024, then increased by 26.86% to 92284000.0 in 2025, then sank by 108.23% to 192166000.0 in 2026.
- Business Quant data shows NTLA's Income from Continuing Operations at 192166000.0 in Q1 2026, 92284000.0 in Q4 2025, and 222414000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - | -106.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -106.96 Mn |
| Mar 31, 2026 | -95.33 Mn |
| Dec 31, 2025 | -92.23 Mn |
| Sep 30, 2025 | -104.76 Mn |
| Jun 30, 2025 | -102.59 Mn |
| Mar 31, 2025 | -112.20 Mn |
| Dec 31, 2024 | -125.82 Mn |
| Sep 30, 2024 | -132.65 Mn |
| Jun 30, 2024 | -126.62 Mn |
| Mar 31, 2024 | -101.37 Mn |
| Dec 31, 2023 | -127.43 Mn |
| Sep 30, 2023 | -118.37 Mn |
| Jun 30, 2023 | -119.68 Mn |
| Mar 31, 2023 | -99.98 Mn |
| Dec 31, 2022 | -104.73 Mn |
| Sep 30, 2022 | -103.59 Mn |
| Jun 30, 2022 | -97.60 Mn |
| Mar 31, 2022 | -143.71 Mn |
| Dec 31, 2021 | -79.91 Mn |
| Sep 30, 2021 | -71.64 Mn |